What’s New in HCC

 

Insights from 2023 ASCO® Annual Meeting
S

ASCO® 2023 Insights: "Results From the Pivotal Phase 2b HERIZON-BTC-01 Study - Zanidatamab in Previously-Treated HER2‑Amplified Biliary Tract Cancer"

By Insights from 2023 ASCO® Annual Meeting FEATURING Shubham Pant
By Insights from 2023 ASCO® Annual Meeting FEATURING Shubham Pant
78 views
June 21, 2023
0 Comments
Login to view comments. Click here to Login
What’s New in HCC
07:46
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase II Clinical Trial to Study the Use of Cabozantini…

Feat. S. L. Chan
21:26
NYU Langone

Common TKI Toxicity Management in 2L HCC Treatment

Feat. J. Wu
12:22
City of Hope

Role of TKIs After 1L IO in Advanced HCC

Feat. D. Li
09:14
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Results From the Pivotal Phase 2b HERIZON…

Feat. S. Pant
06:59
ASCO GI 2023 Conference Coverage

ASCO GI 2023 CCTG HE.1 - Phase 3 Study: Palliative RT for Symptomati…

Feat. L. Dawson
31:47
UChicago Medicine

Multidisciplinary Approach to Hepatobiliary Malignancies: A Changing…

Feat. A. A. Pillai
06:04
PrecisCa

What Is the Role for Systemic Chemo vs. IO for the Treatment of Unre…

Feat. R. Finn
06:50
Daniel Ahn

Mechanism of Action of TKIs in HCC

46:36
Yale Cancer Center

Hepatocellular Carcinoma - From Screening to Treatment: Current Prac…

Feat. T. Taddei